Race Oncology Limited
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need… Read more
Race Oncology Limited (RAONF) - Total Liabilities
Latest total liabilities as of June 2024: $1.92 Million USD
Based on the latest financial reports, Race Oncology Limited (RAONF) has total liabilities worth $1.92 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Race Oncology Limited - Total Liabilities Trend (2013–2024)
This chart illustrates how Race Oncology Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Race Oncology Limited Competitors by Total Liabilities
The table below lists competitors of Race Oncology Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fuzul Gayrimenkul Yatirim Ortakligi Anonim Sirketi
IS:FZLGY
|
Turkey | TL4.75 Billion |
|
Zhejiang Huaye Plastics Machinery Co., Ltd.
SHE:301616
|
China | CN¥383.56 Million |
|
DHAWF
PINK:DHAWF
|
USA | $610.64 Million |
|
Teamlease Services Limited
NSE:TEAMLEASE
|
India | ₹13.39 Billion |
|
Euroapi S.A
PINK:EAPIF
|
USA | $488.40 Million |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
Turkey | TL51.07 Billion |
|
Harum Energy Tbk PT
JK:HRUM
|
Indonesia | Rp1.46 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Race Oncology Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Race Oncology Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Race Oncology Limited (2013–2024)
The table below shows the annual total liabilities of Race Oncology Limited from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | $1.92 Million | +66.39% |
| 2023-06-30 | $1.15 Million | -18.74% |
| 2022-06-30 | $1.42 Million | +170.95% |
| 2021-06-30 | $523.11K | +114.70% |
| 2020-06-30 | $243.65K | +26.82% |
| 2019-06-30 | $192.12K | -37.97% |
| 2018-06-30 | $309.71K | -14.82% |
| 2017-06-30 | $363.57K | -7.16% |
| 2016-06-30 | $391.62K | +229.70% |
| 2015-06-30 | $118.78K | -10.05% |
| 2014-06-30 | $132.05K | +1014.31% |
| 2013-06-30 | $11.85K | -- |